18:56 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported updated data from 14 patients with advanced adenoid cystic carcinoma (ACC) in an expansion cohort of the Phase Ib/II BBI503-101 trial showing...
18:55 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from 14 patients with hepatocellular carcinoma (HCC) in the Phase Ib/II BBI608-503-103HCC trial showing that twice-daily 160 or 240 mg oral...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Amcasertib: Updated Phase I data

Updated data from 13 patients with adenoid cystic carcinoma (ACC) in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that once-daily 10-300 mg oral amcasertib led to a median PFS...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Amcasertib: Additional Phase I data

Data from 15 patients with squamous cell carcinoma of the head and neck (SCCHN) and 5 patients with parotid/salivary tumors in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

BBI503: Phase I data

Data from 20 evaluable patients with advanced solid tumors in the single-arm, open-label, dose-escalation, North American Phase I BBI503-101 trial showed that once-daily 10-450 mg doses of oral BBI503 led to 11 cases of stable...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Dainippon Sumitomo cancer news

Dainippon launched Boston Biomedical Pharma Inc. to focus on the commercialization of cancer therapies, including Dainippon's BBI608 . The product, a small molecule targeting cancer stem cells, is in Phase III testing to treat colorectal...
07:00 , Mar 19, 2012 |  BioCentury  |  Strategy

Incentivized success

Boston Biomedical Inc. 's story shows what can happen when researchers are given the imperative and the resources to invent as if their livelihoods depend on it. The company emerged from ArQule Inc. in 2006...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Boston Biomedical, Dainippon Sumitomo deal

Dainippon will acquire cancer stem cell company Boston Biomedical for $200 million up front, plus up to $540 million in development milestones and up to $1.9 billion in sales milestones. Dainippon will gain BBI608 and...
01:11 , Mar 1, 2012 |  BC Extra  |  Top Story

Dainippon to acquire Boston Biomedical

Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) will acquire cancer stem cell company Boston Biomedical Inc. (Norwood, Mass.) for $200 million up front, plus up to $540 million in development milestones and up to $1.9...